AZN/ROG: Roche/AZN: SERDs restrict or fail

We continue to see well below consensus prospects for Roche’s selective oestrogen receptor degrader (SERD) giredestrant, facing stiff competition from AZN’s camizestrant and already FDA approved alternative elacestrant [Menarini]. Despite the apparent broader success of the AZN competitor, we only see real first line prospects restricted